In contrast, pharmacological blockade of KCa3.1 with TRAM-34 sensitizes glioblastoma cells to the DNA-alkylating agent temozolomide (TMZ), which is used for standard therapy of malignant glioma [16]. Here, KCNN4 is linked to glioblastoma.